Increased PDPK1 expression promotes gemcitabine resistance in pancreatic adenocarcinoma cells (Li et al., 2018) and radiation resistance in hepatocellular carcinoma (Bamodu et al., 2020). Here, PDPK1 is linked to pancreatic adenocarcinoma.